Mannose-Functionalized Isoniazid-Loaded Nanostructured Lipid Carriers for Pulmonary Delivery: In Vitro Prospects and In Vivo Therapeutic Efficacy Assessment

Author:

Ahalwat Shaveta1,Bhatt Dinesh Chandra2,Rohilla Surbhi2,Jogpal Vikas1,Sharma Kirti1,Virmani Tarun3ORCID,Kumar Girish3ORCID,Alhalmi Abdulsalam4ORCID,Alqahtani Ali S.5ORCID,Noman Omar M.5ORCID,Almoiliqy Marwan6

Affiliation:

1. School of Medical and Allied Sciences, G. D. Goenka University, Gurugram 122103, India

2. Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar 125001, India

3. School of Pharmaceutical Sciences, MVN University, Palwal 121105, India

4. Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India

5. Department of Pharmacognosy, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia

6. Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Abstract

Resistance to isoniazid (INH) is common and increases the possibility of acquiring multidrug-resistant tuberculosis. For this study, isoniazid-loaded nanostructured lipid carriers (INH-NLCs) were developed and effectively functionalized with mannose (Man) to enhance the residence time of the drug within the lungs via specific delivery and increase the therapeutic efficacy of the formulation. The mannose-functionalized isoniazid-loaded nanostructured lipid carrier (Man-INH-NLC) formulation was evaluated with respect to various formulation parameters, namely, encapsulation efficiency (EE), drug loading (DL), average particle size (PS), zeta potential (ZP), polydispersity index (PDI), in vitro drug release (DR), and release kinetics. The in vitro inhalation behavior of the developed formulation after nebulization was investigated using an Andersen cascade impactor via the estimation of the mass median aerosolized diameter (MMAD) and geometric aerodynamic diameter (GAD) and subsequently found to be suitable for effective lung delivery. An in vivo pharmacokinetic study was carried out in a guinea pig animal model, and it was demonstrated that Man-INH-NLC has a longer residence time in the lungs with improved pharmacokinetics when compared with unfunctionalized INH-NLC, indicating the enhanced therapeutic efficacy of the Man-INH-NLC formulation. Histopathological analysis led us to determine that the extent of tissue damage was more severe in the case of the pure drug solution of isoniazid compared to the Man-INH-NLC formulation after nebulization. Thus, the nebulization of Man-INH-NLC was found to be safe, forming a sound basis for enhancing the therapeutic efficacy of the drug for improved management in the treatment of pulmonary tuberculosis.

Funder

King Saud University, Riyadh, Saudi Arabia

Publisher

MDPI AG

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Reference52 articles.

1. Tuberculosis: A Disease without Boundaries;Fogel;Tuberculosis,2015

2. Miggiano, R., Rizzi, M., and Ferraris, D.M. (2020). Mycobacterium tuberculosis Pathogenesis, Infection Prevention and Treatment. Pathogens, 9.

3. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis;Seung;Cold Spring Harb. Perspect. Med.,2015

4. Tuberculosis Epidemiology, Pathogenesis, Drugs and Drug Resistance Development: A Review;Kebede;J. Biomed. Sci.,2019

5. Tuberculosis—An Overview;Agyeman;J. Public Health Emerg.,2017

Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3